Other cohort studies on cancer patients with CD26 inhibitor intake have shown a better long-term outcome in colorectal (7) or prostate cancers (8), while patients with pancreatic or breast cancer did not have this favorable effect (8). The gene discussed is DPP4; the disease is prostate cancer.